SOURCE: Active Biotech

May 13, 2008 02:41 ET

Active Biotech advances ANYARA into Phase III clinical trial

LUND, SWEDEN--(Marketwire - May 13, 2008) - Lund, Sweden, May 13, 2008 - An interim analysis has been performed in Active Biotech AB's (OMX Nordic: ACTI) ongoing Phase II/III clinical study of ANYARA, in patients with advanced renal cell cancer.


Active Biotech advances ANYARA into Phase III clinical trial -- http://hugin.info/1002/R/1218474/255317.pdf




Copyright © Hugin AS 2008. All rights reserved.

Contact Information

  • For further information, please contact:

    Goran Forsberg
    VP Communication & Business Development
    Tel +46 (0)46-19 11 54
    Email Contact